Gonadal and sexual function are key to quality of life following bone marrow transplantation (BMT), but no large studies have been published on Leydig cell (LC) function in adults. LC insufficiency (LCI) can cause premature andropause with its consequences including sexual morbidity from diminished libido and erectile dysfunction (ED). In addition, LCI can result in generalised fatigue and even osteopenia. We reviewed gonadal function pre-transplant (immediately prior to BMT) and at 3-18 months post BMT in 117 patients who underwent BMT for a variety of haematological malignancies. The patients presented with variable degrees of symptoms of LCI, such as fatigue, diminished sex drive and libido or ED. The results suggest that the patients sustained severe gonadal damage to both their germ cells (GC) as well as the LC compartment (P Ͻ 0.001). We characterised two distinct functional subsets of LC insufficiency: Type I: compensated type with high LH and normal T levels and low T/LH ratio: (n = 102); and type II: uncompensated type (premature andropause) with high LH and low testosterone levels with low T/LH ratio (n = 15). Although type II patients had more severe LC damage than type I, patients in both groups were symptomatic. We recommend that symptomatic patients in both groups may benefit from a therapeutic trial with testosterone replacement treatment (TRT) for 3-6 months. Bone Marrow Transplantation (2001) 28, 497-502.
applies to patients with solid tumours, 1 as well as to patients with haematological malignancies 2 undergoing conventional chemotherapy or BMT.
Severe hypogonadism is anticipated following high-dose chemo-radiotherapy and BMT for haematological malignancies. 3, 4 Although most studies relating to hypogonadism focus on germ cell damage, less mitotically active Leydig cells are also vulnerable to high-dose chemo-radiotherapy and BMT. 5 Diagnosis of LCI can be difficult unless patients are symptomatic and present with frank andropause with low testosterone (T) levels and diminished libido. However, LCI may be a purely biochemical diagnosis where Leydig cell reserve is diminished (serum testosterone level is normal or even high-normal but LH level is elevated). This condition is known as compensated LCI which can be best diagnosed by the Human Chorionic Gonadotrophin challenge test. A low T/LH ratio and low HCG stimulated T levels are hallmarks of LCI, and a diagnosis of compensated and uncompensated LCI is important as both groups have target organ insufficiency and may benefit from TRT, if symptomatic. We 6 have shown compensated Leydig cell insufficiency in recipients of BMT who had low HCGstimulated T levels and were asymptomatic. A similar picture is shown in many recipients of conventional multiagent chemotherapy for haematological and other malignancies. 5, 7, 8 However, no large study has been published on LC function in adult recipients of BMT. LCI can cause significant sexual morbidity from diminished libido, erectile dysfunction, generalised fatigue and even osteopenia. Although we showed compensated LCI to occur as early as 3 months post BMT, in our previously reported prospective study, 6 the patient number was inadequate to characterise functional subsets of LCI.
We undertook this retrospective study in recipients of BMT with the following three aims: (1) to characterise the type and severity of LCI; (2) to determine whether age, underlying haematological disease, previous treatment, conditioning regimen (chemotherapy vs radiotherapy), or type of transplantation (autologous vs allogeneic) can influence the degree of LCI; and (3) to establish the correlation between degree of LCI and germ cell (GC) damage. Such information may promote better understanding of the severity of LCI and help promote the best therapeutic options.
Patients and methods
In this retrospective study, we assessed gonadal function pre-BMT (immediately prior to BMT) and 3-18 months post BMT, in 117 patients. These patients were referred to the reproductive medicine unit for fertility counselling and assessment of endocrine function. Patient characteristics, endocrine data and libido at presentation are given in Table  1 . One hundred and seventeen male patients with haematological malignancies who underwent either an autologous or allogeneic bone marrow transplant were studied. The median age was 34 years . Thirty-five patients had non-Hodgkin's lymphoma (NHL), 36 Hodgkin's disease (HD), 17 acute myeloid leukaemia (AML), 11 acute lymphoblastic leukaemia (ALL), 12 multiple myeloma (MM), and six chronic myeloid leukaemia (CML). Ninety-five patients received an autologous bone marrow/peripheral blood stem cell transplant and 22 patients an allogeneic one. In 19 recipients of allogeneic bone marrow transplant the donor was an HLA matched sibling and in three an HLA matched unrelated donor. All patients had multi-agent chemotherapy prior to BMT. Transplant type and preparative regimen are given in Table 1 . All recipients of an allogeneic transplant received cyclosporine A plus methotrexate as graft-versus-host disease (GVHD) prophylaxis. Pretransplant findings were compared with those of the 10 healthy controls aged 25-50 years.
Assessment of gonadal function
Testicular function was assessed by testicular volume (orchidometer). GC was assessed by measuring serum follicle stimulating hormone (FSH); LC function was assessed by measuring luteinising hormone (LH) and testosterone (T) levels. Elevated FSH and LH levels of Ͼ10 IU/l were used as markers of GC and LC damage, respectively. Hypotestosteronaemia was defined as T values of Ͻ10 nmol/l. T/LH ratio was also used to assess LC function. Thyroid function (free T4, TSH) and serum prolactin were also measured.
Measurement of hormones
Concentrations of FSH, LH and T were measured by radioimmunoassay by a double antibody technique 3 using commercially available kits.
Statistics
The Wilcoxon signed rank test was used to compare prevs post-transplant hormone levels. FSH, LH and testosterone (pre-and post-transplant levels) in the autologous vs allogeneic and the TBI vs chemotherapy group, were compared using the non-parametric Mann-Whitney U test.
Pearson's correlation was used to compare differences in post transplant vs pre-transplant, FSH, LH and T/LH.
Results
The patients presented with variable symptoms of LCI, such as fatigue, diminished sex drive and libido or erectile dysfunction. This was assessed by questionnaire. Patients sustained severe gonadal damage to both their GC and LC compartments. Using Pearson's correlation, there was a statistically significant positive correlation when comparing difference (post transplant Ϫ pre-transplant) FSH with difference LH (P Ͻ 0.001) (Figure 1 ). There was a suggestion that patients who received TBI in their preparative regimen sustained more damage in their GC compartment as compared to those who received only chemotherapy (P = 0.06). However a regression model showed no evidence of a difference. Similarly, recipients of allogeneic transplantation experienced significantly more severe damage to the GC compartment compared to those who received an autologous transplant (P = 0.02). On attempting to fit a regression model removing outliers so that the data were normally distributed, weak evidence of a difference was found, however, this was not statistically significant at the 5% level (P = 0.07).
There was no difference in the LC compartment among recipients of TBI vs chemotherapy or autologous vs allogeneic transplant.
No correlation was found in age, type of the disease or type of transplant and severity of either GC or LC insufficiency. The most powerful factor which determined the degree of LC insufficiency was the antecedent therapy. Those who had hypogonadism prior to BMT sustained more damage regardless of the type of the preparative regimen prior to BMT. Two distinct functional subsets of LC insufficiency were characterised: type I: compensated type with high LH and normal T levels (n = 103), and type II: uncompensated/frank type (premature andropause), where LH was high with low testosterone levels (n = 15). Both groups had diminished T/LH ratios post-transplant compared to their pre-transplant levels (P = 0.01), indicating damage to the LC compartment. However, there was no evidence of a relationship between degree of functional insufficiency of the LC and the clinical manifestations (ie diminished libido, ED).
Patients with uncompensated/frank type of LC insufficiency had a 2.92 times increase in the FSH compared to those with compensated type (P = 0.02, s.e. 1.28, 95% CI 0.39-5.45).
Discussion
This retrospective study shows evidence of hypergonadotrophic hypogonadism (primary testicular failure), in a large cohort of recipients of BMT for haematological malignancies. This is not surprising as in a prospective study we have shown that testicular damage is an acute effect which occurs within 2-3 months post transplantation and affects both germ and Leydig cell compartments. 6 The severe damage to GC was shown from diminished testicular volume, azoospermia and elevated FSH. In that study we showed elevated basal and gonadotrophin releasing hormone (GnRH) stimulated LH levels. The low basal and HCG 45 N Auto = autologous; Allo = allogeneic; MUD = matched unrelated donors; Tx = transplant; FSH = follicle stimulating hormone; LH = luteinising hormone; Cyclo = cyclophosphamide; TBI = total body irradiation; BEAM = BCNU, etoposide, cytarabine, melphalan; Melph = melphalan; Bus = busulphan; Etop = etoposide; NHL = non-Hodgkin's lymphoma; HD = Hodgkin's disease; AML = acute myeloid leukaemia; ALL = acute lymphoblastic leukaemia; CML = chronic myeloid leukaemia; MM = multiple myeloma; Testos = testosterone; N = normal; L = low. *Uncompensated LC insufficiency.
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stimulated testosterone confirmed evidence of diminished steroidogenic reserve in the BMT patients. This is comparable to the studies of Howell and Shalet, 3 who also showed diminished LC reserve in the chemotherapy-treated patients.
In contrast to our previously reported small series where premature andropause was not detectable, as all patients had compensated LCI, in this study we found two distinct functional subsets of LCI. This was a purely biochemical diagnosis: compensated (type I) and uncompensated (type II). This is the first study where two functional subsets of LCI have been characterised in a large series of BMT recipients. Although type II patients had more severe LC damage than did type I, they did not suffer more severe clinical symptoms compared with the compensated type. In fact, there was no correlation between the biochemical severity of LCI and clinical picture such as libido and ED. This is not surprising as sexual dysfunction, diminished libido and fatigue are multifactorial and factors other than LCI such as psychogenic and disease-related may also have contributed. However, this study showed a positive correlation between the severity of germ and Leydig cell damage with
Bone Marrow Transplantation a suggestion that these two compartments may be affected differently depending on the therapeutic modalities used. For instance, patients who had a TBI-based regimen, suffered more damage to their GC compartment. This is to be expected as it is well known that GC are highly susceptible to radiotherapy. 5, 9 Our patients did not have any history of previous gonadal infection, gonadal injury or other factors which can cause elevated gonadotrphins. 10 An age-related rise in gonadotrophins 11, 12 is unlikely, as only a small proportion of patients (6.8%) were older than 55 years. Therefore, the cause of LCI with a concomitant rise in serum LH is likely to be hypogonadism. Of all the factors affecting LCI, we found antecedent treatment to correlate most strongly with the degree of LC damage. This is comparable to our previous study 6 where LC dysfunction was demonstrated (from basal and HCG stimulated testosterone levels) even prior to transplantation, suggesting that steroidogenic capacity is vulnerable to conventional doses of chemotherapy. This is understandable as our patients had had at least two lines of chemotherapy before undergoing highdose therapy. The impact of chemotherapy on testicular function used for the treatment of haematological malignancies and especially for lymphomas has been widely reported. [13] [14] [15] However, it is also important to appreciate that disease-related hypogonadism cannot be ruled out.
We have demonstrated that LC insufficiency is heterogeneous, ranging from a physiologically compensated type to frank failure, which may lead to premature andropause. Although gonadal dysfunction following high-dose treatment may be temporary, recovery is highly unpredictable and it is possible that the compensated type may lead to frank failure in the course of time, as damage is likely to be permanent in a proportion of patients. 3 Also, ageing can aggravate the existing problem of LCI due to hypogonadism. 16 We have shown that LCI is more likely to be severe in patients who had had high-dose treatment and especially to those who had sustained severe damage prior to BMT. Nevertheless, biochemical damage may not be proportional to the severity of clinical symptoms due to variable factors such as target organ sensitivity or individual variation of clinical response.
It is well known that the post-pubertal testis is more vulnerable to damage than the pre-pubertal counterpart. 17 Unlike with females, age at transplant is less important for testicular damage. However in one study by Mertens et al, 5 it was shown that older males were more vulnerable to testicular damage, especially to their GC compartment. However, little is known about the natural history of damage to the LC compartment and potential for recovery. Although some investigators have shown hypogonadism to be age related, this mainly relates to germ cell damage 18, 19 and little is known about the relationship between age and LC damage. A previous study by Shalet et al 20 showed that radiotherapy-induced LC damage is age related. However, in our study we found the degree of LCI to be independent of age.
The use of TRT in andropausal men with sexual dysfunction has not been established in routine clinical practice. However, three recent studies [21] [22] [23] have shown that TRT is a useful tool in patients with ED. In a recent study, 24 we have also shown evidence of cavernosal arterial insuf-Bone Marrow Transplantation ficiency as well as hypogonadism with LCI in a similar group of BMT recipients. Therefore, TRT may have an added advantage in diminishing cavernosal insufficiency in patients with ED in addition to improving libido.
To establish criteria for selection of patients for a trial of androgen therapy a large randomised placebo-controlled study is required.
In conclusion, our study shows two functional subsets of LCI, the frank and the compensated type, the severity of which is dependent on antecedent chemotherapy. Although the uncompensated have more severe damage than the compensated, it is likely that in future years these patients may suffer frank LCI due to the dual effects of ageing and antecedent high-dose chemotherapy. However, it is impossible to predict which group will show more damage clinically or biochemically. Since some of the symptoms of LCI are potentially treatable, we recommend that a definitive diagnosis of LCI be made first by comprehensive endocrine testing including serum LH and T assays. Then a therapeutic trial with testosterone replacement therapy (TRT) for 3-6 months may be given in symptomatic patients to determine any beneficial effect on sexual dysfunction, especially diminished libido and nocturnal tumescence. These patients must have prostatic ultrasonography to exclude prostatic hyperplasia which may aggravate TRT. 25 
